Schizophrenia guidelines across the world: a selective review and comparison (Q37949405)

25 August 2017

Schizophrenia guidelines across the world: a selective review and comparison (English)

1 reference

25 August 2017

0 references

Wolfgang Gaebel

1

1 reference

PubMed ID

22026495

25 August 2017

Mathias Riesbeck

series ordinal

2

1 reference

PubMed ID

22026495

25 August 2017

Thomas Wobrock

series ordinal

3

1 reference

25 August 2017

1 August 2011

1 reference

International Review of Psychiatry

25 August 2017

1 reference

25 August 2017

23

1 reference

25 August 2017

379-387

1 reference

25 August 2017

4

1 reference

Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project

25 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Outcome of common mental disorders in Harare, Zimbabwe.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

AGREE II: advancing guideline development, reporting and evaluation in health care

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Schizophrenia practice guidelines: international survey and comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Effectiveness and efficiency of guideline dissemination and implementation strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Effects of evidence-based clinical practice guidelines on quality of care: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

A systematic review of longitudinal outcome studies of first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Improving the quality of health care: using international collaboration to inform guideline programmes by founding the Guidelines International Network (G-I-N)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Effects of implementation of psychiatric guidelines on provider performance and patient outcome: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

Quality assurance in psychiatry: quality indicators and guideline implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F09540261.2011.606801

10.3109/09540261.2011.606801

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22026495